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INTRODUCTION
T1D is caused by the autoimmune destruction of insulin-producing 
pancreatic β-cells.1 Current treatment requires daily injections of 
insulin to control blood glucose levels or transplantation of insulin-
secreting tissue. Since this latter strategy currently relies on a source 
of human tissue, it seems unlikely that there will ever be sufficient 
numbers of organs available to assist the number of insulin-depen-
dent diabetics that require transplantation.2 Additionally, these 
patients would have to be under a chronic regimen of immunosup-
pressive drugs to prevent both rejection of the transplanted tissue 
and recurrent autoimmunity. The autoimmune destruction of islet 
cells could theoretically be overcome by genetically engineering an 
“artificial β-cell” (i.e., a nonislet cell) capable of synthesizing, storing, 
and secreting mature insulin in response to metabolic signals. As it 
is not a bona fide pancreatic β-cell, such a cell would not carry the 
complete suite of islet and β-cell antigens responsible for recurrent 
autoimmune reactions. Further, if artificial β-cells were engineered 
from the patient’s own cells, then the patient would be released 
from the need of daily insulin injections, and the debilitating com-
plications of the disease, without the added complications that 
arise from lifelong immunosuppression.
Liver cells have been successfully used as the target cells for 
gene therapy in a number of successful studies,3–11 including the 
generation of artificial β-cells. Hepatocytes are known to play a 
crucial role in the intermediary metabolism, synthesis, and storage 
of proteins. Most importantly, liver cells express the high-capacity 
glucose transporter, GLUT 2 (ref. 12), and the glucose phosphoryla-
tion enzyme, glucokinase,13 which make up the key elements of the 
“glucose sensing system” that regulates insulin release from β-cells 
in response to changes in the external nutrient composition. These 
characteristics make hepatocytes attractive candidates for a gene 
therapeutic approach to curing T1D.
The ultimate goal for gene therapy to cure T1D will involve the 
direct delivery of the insulin gene, and other genes required for reg-
ulating the response to glucose, into a patient’s own cells (thereby 
circumventing issues of allograft rejection). The engineering of a 
β-cell from a non-β-cell precursor, such as hepatocytes, also has 
the advantage of putatively minimizing the magnitude of recurrent 
autoimmune responses, due to the absence of the entire suite of 
β-cell autoantigens expressed by pancreatic β-cells. However, cur-
rently, the most efficient vehicles available to deliver genes directly 
to the primary cells of an individual’s body are viral vectors, such as 
retroviral, lentiviral, or adenoviral.5–11 Presently, there are several hur-
dles surrounding the transfer of viral material with the available viral 
vector systems,14 such as logistics and safety concerns. This makes 
the development of an artificial β-cell line, which can control blood 
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Correction of diabetes using Melligen cells
As an alternative to the transplantation of islets, a human liver cell line has been genetically engineered to reverse type 1 diabetes 
(TID). The initial liver cell line (Huh7ins) commenced secretion of insulin in response to a glucose concentration of 2.5 mmol/l. After 
transfection of the Huh7ins cells with human islet glucokinase, the resultant Melligen cells secreted insulin in response to glucose 
within the physiological range; commencing at 4.25 mmol/l. Melligen cells exhibited increased glucokinase enzymatic activity in 
response to physiological glucose concentrations, as compared with Huh7ins cells. When transplanted into diabetic immunoin-
competent mice, Melligen cells restored normoglycemia. Quantitative real-time polymerase chain reaction (qRT-PCR) revealed that 
both cell lines expressed a range of β-cell transcription factors and pancreatic hormones. Exposure of Melligen and Huh7ins cells 
to proinflammatory cytokines (TNF-α, IL-1β, and IFN-γ) affected neither their viability nor their ability to secrete insulin to glucose. 
Gene expression (microarray and qRT-PCR) analyses indicated the survival of Melligen cells in the presence of known β-cell cyto-
toxins was associated with the expression of NF-κB and antiapoptotic genes (such as BIRC3). This study describes the successful 
generation of an artificial β-cell line, which, if encapsulated to avoid allograft rejection, may offer a clinically applicable cure for T1D.
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glucose levels and be delivered to the patient in an encapsulation 
system, perhaps a more attractive, and realistic, alternative than the 
direct delivery of genes to body tissues in vivo using viral vectors.
Well-designed encapsulation systems can protect the enclosed 
cells against exposure to the immune cells, notably cytotoxic T cells, 
which mediate allograft and autoimmune reactions. However, the 
encapsulated cells will still be exposed to immune mediators, such 
as proinflammatory cytokines, which played major roles in the ini-
tial autoimmune destruction of the β-cell population.15 For an arti-
ficial β-cell line to be a realistic cure for diabetes, it must fulfill two 
criteria: (i) the ability to secrete insulin in response to glucose in the 
physiological range, and (ii) the ability to retain viability in the pres-
ence of cytokines secreted during Thelper (Th)1/Th17 proinflamma-
tory immune responses that precipitate autoimmune diabetes.16,17
The expression of GLUT2 and glucokinase (hexokinase IV), the 
predominant glucose transporter and glucose phosphorylating 
enzyme, respectively, is central to the ability of pancreatic β-cells, 
and insulinoma cell lines, such as INS-1 (ref. 18) and MIN6 (ref. 19), 
to respond to glucose in the physiological range. Other insulinoma 
cell lines, such as RIN 1046-38 cells,20 do not respond to glucose in 
the physiological range, and express only negligible/low levels of 
GLUT 2. Other studies have shown that the overexpression of GLUT 
2 alone, or in combination with glucokinase, significantly improved 
the range of response to glucose of engineered insulin secreting 
cells.21,22 However, physiological glucose responsiveness cannot be 
achieved solely by the expression of the glucokinase and hexoki-
nase enzymes. The ratio of glucokinase:hexokinase expression has 
been implicated in the maintenance of physiological glucose secre-
tion.22,23 For example, an imbalance in the glucokinase:hexokinase 
ratio, in favor of hexokinase, enhances glycolytic flux at low glucose 
levels and consequently an inappropriate glucose-stimulated insu-
lin secretion response results.22,23
Previously, our laboratory developed an artificial β-cell line, 
Huh7ins,4 which exhibited a number of desirable characteristics 
for potential use in the gene therapy of diabetes. Firstly, Huh7ins 
cells exhibited endogenous expression of the specific glucose 
transporter, GLUT 2, and the key glycolytic enzyme, glucokinase. 
Secondly, Huh7ins cells were able to synthesize, store and secrete 
insulin in response to glucose. Thirdly, the insulin produced by 
Huh7ins cells was stored in secretory granules that morphologically 
resembled those observed in pancreatic β-cells. Fourthly, Huh7ins 
cells expressed proinsulin convertase 1 and 2, which are the 
enzymes responsible for the conversion of proinsulin to insulin in 
pancreatic β-cells. Fifthly, Huh7ins cells responded to a glucose stim-
ulus, via the activation of ATP-dependent K+ and calcium channels, 
akin to pancreatic β-cells.24 Finally, and perhaps most significantly, 
Huh7ins cells normalized blood glucose levels when transplanted 
into diabetic immune-incompetent (NOD/scid) mice, indicating 
that they retained the ability to secrete insulin in response to glu-
cose following transplantation. However, after transplantation into 
diabetic recipients and subsequent reversion to normoglycemia, 
Huh7ins cells secreted insulin in response to subphysiological glu-
cose concentrations (2.5 mmol/l), in contrast to pancreatic β-cells, 
which commenced insulin secretion at glucose concentrations of 
4–5 mmol/l. Consequently, animals transplanted with Huh7ins cells 
developed chronic hypoglycemia. Therefore, before Huh7ins cells 
could be considered for potential clinical use, further molecular 
engineering strategies needed to be implemented to correct the 
range in which glucose stimulated insulin secretion.
The current study describes the re-engineering of Huh7ins cells 
to produce a novel cell line, termed Melligen, which stored insulin 
and secreted it in the physiological range and reversed diabetes in 
NOD/scid mice, without the induction of hypoglycemia. Melligen 
cells were also resistant to the toxic effects of proinflammatory 
cytokines that have been shown to induce the death of pancreatic 
β-cells and β-cell lines. The Melligen cells are the first truly glucose-
responsive, nonpancreatic, insulin-secreting human cell line to be 
developed. As such Melligen cells warrant further investigation to 
assess their clinical potential to cure autoimmune diabetes.
ReSUlTS
Gene transfer into Huh7ins cells
Huh7ins cells were stably transfected with the pIRESpuro3 vector 
carrying human glucokinase cDNA and 6 clones of Huh7ins cells 
expressing glucokinase were isolated and assayed for glucose-
responsive insulin secretion. The transfectants remained stable for a 
period of greater than 6 months in continuous culture.
Insulin secretion and storage
In response to increasing concentrations of glucose (1–20 mmol/l), a 
dose–response curve for insulin secretion was generated for Huh7ins 
cell clones transfected with human islet glucokinase and compared 
with that for the parent Huh7ins cells (Figure 1a,b). It can be seen 
in Figure 1a that while glucose responsiveness commenced at 2.5 
mmol/l in Huh7ins cells, it commenced in the physiological range 
Figure 1 Insulin secretion from liver cell lines: Insulin secretion from (a) Huh7ins and (b) Melligen cells in response to increasing concentrations of 
glucose: 1.5–20 mmol/l. (c) Insulin secretion from Melligen cells in response to increasing concentrations of glucose: 3.75–5.0 mmol/l. Values are 
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(between 4–5 mmol/L) in the Huh7ins cells transfected with human 
islet glucokinase (Figure 1b). The actual amount of insulin secreted in 
response to glucose in the physiological range for clone 6 Huh7ins 
cells transfected with glucokinase, was also double that of the parent 
Huh7ins cells (also an advantageous development). Accordingly, clone 
6 was used in all subsequent experiments, and the cells of this clone 
were designated Melligen cells. Glucose response assays performed 
using Huh7ins cells transfected with the empty vector revealed that 
their glucose responsiveness was not significantly different from the 
Huh7ins cells (results not shown). The exact concentration of glucose 
at which Melligen cells commenced glucose-responsive insulin secre-
tion was determined to be 4.25 mmol/l (Figure 1c).
The storage of insulin in Huh7ins cells and Melligen cells was 
measured and no differences in insulin storage were observed: 
8.5 ± 0.7 pmoles insulin/106 cells (n = 3) for Huh7ins cells transfected 
with the empty vector and 8.7 ± 0.9 pmoles insulin/106 cells (n = 3) 
for Melligen cells.
Reversal of diabetes in NOD/scid mice
Transplanted Melligen cells coalesced into a mass at the site of graft-
ing and grafts were visible under the skin 1–2 weeks after the cells 
were transplanted. All 16 diabetic mice that were transplanted with 
either Melligen (n = 8) or Huh7ins (n = 8) cells reverted to normoglyce-
mia within 19 days post-transplantation. Blood glucose levels of ani-
mals transplanted with Melligen cells remained normoglycemic (5.2–
5.7 mmol/l) until removal of the graft at day 27 post- transplantation. 
By comparison, diabetic animals that were transplanted with Huh7ins 
cells became hypoglycemic from day 21 (3.1 ± 0.4 mmol/l on day 19 
decreasing to 2.6 ± 0.7 mmol/l on day 27) (Figure 2a). Removal of the 
Huh7ins or Melligen grafts at day 27 resulted in an immediate increase 
in the blood glucose levels to hyperglycemic values (Figure 2a). These 
results indicated that reversal of hyperglcemia was not attributable to 
regeneration of pancreatic β-cells.
The fasting blood glucose levels of mice transplanted with 
Huh7ins cells were significantly lower than untreated normal con-
trols (Figure 2b). During the intraperitoneal glucose tolerance 
tests, the glucose dose–response curve for mice transplanted with 
Huh7ins cells peaked at significantly lower blood glucose levels 
(16.3 ± 0.6 mmol/l, P < 0.01) when compared to normal untreated 
animals (21.5 ± 0.9 mmol/l), and by 120 minutes blood glucose levels 
had returned to hypoglycemic levels (2.6 ± 0.3 mmol/l). Importantly, 
there was no significant difference between the intraperitoneal glu-
cose tolerance test results for animals transplanted with Melligen 
cells and the untreated normal controls (Figure 2b). A scatter plot of 
18 hours fasting blood glucose values for the animals in Figure 2b 
(Supplementary Figure S1) shows little variation in the groups of 
transplanted animals.
After grafts of Melligen and Huh7ins cells were excised, it was 
determined if alternative cells were producing insulin, or other 
pancreatic hormones. Figure 3a shows extensive staining for insu-
lin (75.3 ± 6.5% of total graft cells) and a small amount of stain-
ing for glucagon (1.1 ± 0.1% of total graft cells) and somatostatin 
(0.1 ± 0.02% of total graft cells) in the Melligen cell graft. Less than 
1% of cells showed expression of all three hormones. The remain-
der of the tissue that did not stain for either hormone, was likely 
Figure 2 Reversal of diabetes in NOD/scid mice following transplantation 
of Huh7ins and Melligen cells: (a) Blood glucose levels of NOD/scid mice 
transplanted with Huh7ins and Melligen cells and diabetic controls. 
Grafts of Huh7ins and Melligen cells were removed at 27 days. (b) 
Intraperitoneal glucose tolerance test in mice transplanted with Huh7ins 
and Melligen cells, normal and diabetic controls. Values are expressed as 




















































Figure 3 Expression of pancreatic hormones following reversal of 
diabetes in NOD/scid mice following transplantation of Melligen cells. 
(a–c) Photomicrographs of triple anti-insulin (INS), anti-somatostatin 
(SST), and anti-glucagon (GLUC) staining of (a) Melligen graft, (b) normal 
mouse pancreas, and (c) diabetic mouse pancreas; original magnification, 
400×. (d) Transmission electron micrograph showing secretory vesicles 
with dense granules (g) (bar = 250 nm) in Melligen grafts, 30 days after 
transplant. (e) Immunoelectron micrograph showing localization of 
insulin in Melligen grafts, 30 days after transplant (bar = 300 nm).
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connective tissue. By comparison, insulin was present in the Huh7ins 
cell graft (70 ± 5.35% of total graft cells), but no staining for soma-
tostatin and glucagon was seen in grafts removed from animals 
transplanted with Huh7ins cells (results not shown). Not surpris-
ingly, extensive staining of insulin, glucagon, and somatostatin was 
seen in the pancreas from normal control animals (Figure 3b). As 
expected, insulin staining was minimal in the pancreas of diabetic 
animals that were engrafted with Melligen cells (Figure 3c) or in 
untreated diabetic animals. Electron microscopy revealed the pres-
ence of cytoplasmic granules (270–330 nm in diameter) in Melligen 
cell grafts (Figure 3d), which were of a similar size and appearance to 
those in pancreatic β-cells.25 Immunoelectron microscopy of insu-
lin-producing cells in the grafts indicated that insulin was stored in 
the granules (Figure 3e).
Glucokinase and hexokinase enzyme activities
To examine the ratio of glucokinase: hexokinase expression in 
Melligen cells, glucokinase protein and enzymatic activity in 
Huh7ins and Melligen cells were measured. Qualitative western 
analysis showed the presence of human glucokinase in Melligen, 
Huh7ins, and MIN6 cells, but there was an upregulation in expres-
sion levels of glucokinase protein in the Melligen cells (Figure 4). 
The qualitative changes in protein expression, as determined from 
western analyses, may be correlated with estimates of glucoki-
nase enzymatic activity determined in extracts from the cell lines. 
Huh7, Huh7ins, and Huh7ins-empty vector cells contained 16 ± 1.2, 
24.2 ± 2.3, and 25.4 ± 2.6 U/g protein of glucose phosphorylating 
activity, respectively when assayed at 20 mmol/l glucose (Figure 5a) 
in the absence of glucose-6-phosphate. This activity was reduced to 
3.0 ± 0.5, 4.8 ± 0.4, and 4.7 ± 0.5 U/g protein, respectively, when the 
assay was conducted in the presence of 10 mmol/l glucose-6-phos-
phate (Figure 5b). This finding was consistent with the premise that 
most (~80%) of the enzymatic activity was contributed by low Km 
glucose-6-phosphate sensitive hexokinases in the Huh7 cell lines. 
By comparison, Melligen cells had a significantly higher (P < 0.01) 
level of glucose-phosphorylating capacity, as compared to the other 
cell lines, of 34.6 ± 3.4 U/g protein when measured in the absence of 
glucose-6-phosphate, and this correlated with the increased pro-
tein concentration seen in the western analysis. More importantly, 
in the presence of glucose-6-phosphate, Melligen cells exhibited a 
threefold enhancement in activity: 20.6 ± 2.7 U/g protein, over the 
Huh7ins cells (4.8 ± 0.1 U/g protein). Therefore, the Melligen cells 
had hexokinase activity that represented 42% of the total glucose 
phosphorylating capacity, as compared to 80% in the other cells, 
and, therefore, had significantly more of the activity contributed by 
glucose-6-phosphate-insensitive glucokinases.
Resistance of Huh7ins and Melligen cells to cytokines
Due to the important role of proinflammatory cytokines in the 
destruction of pancreatic β-cells and transplanted islets, cell viabil-
ity was assessed to establish the cytotoxic effect of various cyto-
kines on Huh7ins, Melligen cells, and the parent cell line, Huh7. After 
establishing the optimized cytokine concentrations that reduced 
the viability of MIN6 β-cells, these experimental parameters were 
applied to the three liver cell lines.
Significant differences were seen in the susceptibility of MIN6 
cells and the human liver cell lines to cytokine-induced toxicity 
from day 3 (P < 0.05). By day 3, cytokine-treated MIN6 cells had via-
bilities of 72 ± 5%, while untreated MIN6 cells grew at an exponen-
tial rate (100 ± 1%) over the 10 days of the experiment. Treatment 
of MIN6 cells with the triple cytokine culture medium (TCCM) for 
10 days caused a significant further decrease in cell viability to 
15 ± 4.5% when compared to untreated cells 100 ± 1% (P < 0.05). 
When exposed to the same cytokine combination for 10 days, Huh7 
cells showed no significant decrease in cell viability, as compared 
to untreated cells. Similarly, in experiments using Huh7ins and 
Melligen cells, there was no significant decrease in cell viability after 
exposure to the triple cytokines over 10 days (results not shown).
Insulin secretion and storage
Cytokine-treated MIN6 cells secreted significantly less insulin (7 ± 3 
pmol/well) than untreated MIN6 cells (39 ± 2 pmol/well) from day 1 
of the incubation (P < 0.05) and throughout the entire period stud-
ied. By day 10, cytokine-treated MIN6 cells had secreted (13.6 ± 2.7 
pmol/well); by comparison, untreated cells had secreted 53.6 ± 8.0 
pmol/well. In contrast, Huh7ins and Melligen cells coincubated with 
cytokines secreted amounts of insulin that were not significantly 
different to their untreated controls. For example, Melligen cells 
Figure 4 Protein expression of glucokinase in liver cell lines. Western 
blot analysis for (a) human glucokinase in Huh7ins cells (lane 1), Huh7 
ins cells with pIRlSpuro3 vector only (lane 2), Melligen cells (lane 3), and 
human islets (lane 4) and (b) GADPH. Human glucokinase generated a 










Figure 5 Enzyme activity of glucokinase in liver cell lines. Glucokinase 
activity of Huh7, Huh7ins, Huh7ins (with pIRlSpuro3 vector only), and 
Melligen cells in the presence of (a) 20 mmol/l glucose and (b) 20 mmol/l 
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treated with TCCM secreted 20.8 ± 0.6 pmol/well at day 10, as com-
pared with 21.9 ± 1.0 pmol/well secreted by untreated cells.
As the cells proliferated, insulin storage steadily increased in 
untreated MIN6 cells over the 10 days of the experiment. After 
exposure of MIN6 cells to the cytokine cocktail, insulin content was 
significantly diminished after day 1, as compared to the control 
MIN6 cells (P < 0.05). The difference between the amounts of stored 
insulin in the treated and untreated MIN6 cells continued to be 
significant throughout the remaining days of the experiment with 
untreated and treated cells reaching 81.9 ± 0.5 pmol/106 cells and 
21.2 ± 1.7 pmol/106 cells by day 10, respectively. In contrast, Huh7ins 
and Melligen cells treated with the cytokine combination did not 
show a significant difference in insulin storage, as compared to the 
untreated Huh7ins and Melligen cells. Untreated Melligen cells, for 
example, stored 8.0 ± 0.2 pmol/106 cells, as compared with 8.9 ± 0.3 
pmol/104 cells for TCCM-treated cells at day 10.
After 10 days of cytokine treatment, MIN6 cells showed a sig-
nificant decrease in insulin response to a glucose stimulus when 
compared to the control MIN6 cells (P < 0.05). Insulin secretion of 
untreated MIN6 cells in response to 20 mmol/l glucose increased 
more than fivefold over 1 hour when compared to basal levels (4 ± 2 
pmol/well/hours) (P < 0.05) (Figure 6a). Treated MIN6 cells did not 
release significantly higher levels of insulin to the glucose stimu-
lus above basal levels (P > 0.05) (Figure 6a). This difference may be 
attributable to reduced viability after 10 days of coincubation with 
cytokines, because control cells continued in the log growth phase, 
as indicated by the trypan blue exclusion assays (results not shown).
The effect of the proinflammatory cytokines treatment on glu-
cose-responsiveness was also determined for the Huh7ins and 
Melligen cells. Untreated Huh7ins and Melligen cells showed a 
five- and sevenfold increase in insulin secretion respectively, when 
stimulated with 20mmol/l glucose, with return to basal levels of 
insulin secretion upon removal of the glucose stimulus (Figure 6b,c). 
Huh7ins and Melligen cells incubated with cytokines for 10 days 
showed the same increase in insulin secretion upon the 20 mmol/l 
glucose stimulus as the untreated cells with a return to basal levels 
of secretion within 1 hour after stimulation (Figure 6b,c). There was 
no  significant difference in the amount of insulin secreted by the 
TCCM treated Huh7ins and Melligen cells during the glucose stim-
ulus (P > 0.05). This data indicated that Huh7ins and Melligen cells 
retained their ability to respond to a glucose stimulus during and 
after 10 days of cytokine treatment. Basal insulin secretion samples 
collected during the course of the experiment also showed no signif-
icant increase in amounts of insulin secreted compared to controls 
(P > 0.05, results not shown).
To determine if TCCM treatment affected the glucose response 
curve between the critical levels of 0–4.5 mmol/l glucose, Huh7ins 
and Melligen cells were cultured for 10 days with and without cyto-
kines. At day 10, the cells were stimulated with increasing concen-
trations of glucose in basal medium. Huh7ins cells commenced 
secretion of increased amounts of insulin to glucose at the sub-
fasting level of 2.5 mmol/l glucose, while Melligen cells secreted 
increased amounts of insulin in response to 4.5 mmol/l glucose 
(Figure 6d). In both cell lines, there was no significant difference 
Figure 6 The effect of cytokine treatment on glucose responsiveness in MIN6, Huh7ins, and Melligen cells. Glucose responsiveness was determined 
using 20 mmol/l glucose stimulus with and without cytokine treatment for (a) MIN6 cells, (b) Huh7ins cells, and (c) Melligen cells after 10 days incubation 
with triple cytokine culture medium (TCCM). The 10-day cytokine treatment did not affect (d) Huh7ins and Melligen cell responsiveness to glucose in 
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observed between cytokine-treated and untreated cells at any glu-
cose concentration (P > 0.05).
Nitric oxide production
The modified Griess reaction was used to determine nitric oxide lev-
els, and hence iNOS activity. The iNOS enzymatic activity was esti-
mated by measurements of nitrite accumulation in tissue culture 
medium, during a 48h exposure to TCCM. MIN6 cells treated with 
TCCM showed significantly (P < 0.05) increased nitrite production at 
both the 24 (10.3 ± 0.5 µmol/l nitrite) and 48 hours (17.9 ± 3.4 µmol/l 
nitrite) time points compared to untreated cells with 8.6 ± 0.1 µmol/l 
nitrite at 24 hours and 9.7 ± 0.2 µmol/l nitrite at 48 hours (n = 5). By 
comparison, the human liver cell lines showed no significant differ-
ence (P > 0.05) in levels of nitrite between treated and untreated 
cells at any time point. For example, the Melligen cells produced 
9.0 ± 0.2 µmol/l nitrite product following 48 hours treatment with 
TCCM, compared with 8.6 ± 0.1 µmol/l nitrite (n = 5) in the untreated 
Melligen cells over the same time period.
RT-PCR and qRT-PCR analysis
Pancreatic hormones and β-cell transcription factors. As expected, 
analysis of Melligen cells by RT-PCR showed the presence of human 
islet glucokinase, which was not detected in the parent cell lines 
(Figure 7a). By comparison, expression levels of other transcription 
factors and hormones that were examined, with the exceptions of 
glucokinase and the pancreatic hormone somatostatin (which was 
only detected in Melligen cells), did not change. Interestingly, glu-
cagon was detected in all liver cell lines and pancreatic polypeptide 
was only detected in human islet tissue. Examination of several key 
factors by qRT-PCR indicated that there was a 2.9 ± 0.9-fold (n = 8) 
increase in Pdx-1 expression, a 2.4 ± 0.4-fold (n = 8) increase in GLUT 
2 expression, a 10.4 ± 1.7-fold (n = 8) increase in islet glucokinase 
expression and a 7.8 ± 0.8-fold (n = 8) increase in somatostatin 
expression in Melligen cells, as compared to Huh7ins. In contrast, 
there were no differences in expression levels of insulin, glucagon, 
Neurod 1 or Neurogenin 3 between Huh7ins and Melligen cells. 
Expression of islet glucokinase and insulin in the Melligen cells was 
maintained following transplantation (Figure 7b).
Cytokine receptor expression. To establish if the observed resistance 
of the Melligen cells to the proinflammatory cytokine cocktail was 
due to the absence of cytokine receptors, RT-PCR was performed 
using cDNA generated from RNA isolated from human islets (posi-
tive control), Huh7, Huh7ins, and Melligen cells. Expression of all 
the tested cytokine receptors was detected, with the exception of 
TNFR2 (which was not expressed in the liver cell lines), and con-
firmed in all cells (Figure 7c).
Genes associated with the NF-ĸB pathway. NF-ĸB exerts different 
effects on cell survival and death depending upon the phenotype 
of the cell. For example, in β-cells, increased expression levels of 
NF-ĸB promote decreased viability while in hepatocytes NF-ĸB acts 
as a survival factor. After treating the cells for 4 hours with TCCM, 
RT-PCR was performed, using human islet cells as a positive control. 
Expression levels of the inhibitors of NF-ĸB, IκBα, IκBβ, and IκBε were 
detected in all cell lines and islets. qRT-PCR analyses indicated that 
all inhibitors were downregulated in Melligen cells: IκBε was down-
regulated by 0.55 ± 0.01-fold (P < 0.05) and IκBα and IκBβ were also 
significantly downregulated by 0.57 ± 0.01-fold and 0.66 ± 0.10-fold, 
respectively (P < 0.05) (n = 3).
Transcriptomics
Exposure of Melligen cells to proinflammatory cytokines modulated 
gene expression levels at 1 and 24 hours after exposure. Using the 
Partek Genomic Suite, PCA mapping of the Gene Array data showed 
that the greater differences in gene expression levels occurred 24 
hours after exposure to cytotoxic cytokines.
After 1 hour exposure of Melligen cells to the cytokines, 17 of 
the 18 genes found to be differentially expressed, were signifi-
cantly upregulated by twofold or more. The upregulated genes 
included the chemokine (C-X-C motif ) ligand family, CXCL1, 
CXCL2, CXCL3, and CXCL10 (Supplementary Table S2). The 
expression of CXCL10 was found to be upregulated by the great-
est degree with a 19-fold upregulation. Interferon regulatory 
factor 1 (IRF1), induced by IFN-γ, was also significantly upregu-
lated. Genes typically induced by IL-1β included TIFA and PTX3. 
Putative NF-κB target genes upregulated in the Melligen cells 
at 1 hour cytokine treatment included baculoviral inhibitor of 
apoptosis protein repeat-containing 3 (BIRC3) and TNFα-induced 
protein 3 (TNFAIP3) with the highest significance level. The only 
gene significantly (P < 0.05) downregulated at 1 hour cytokine 
treatment, compared to 1 hour untreated cells, was NFKBIA (also 
known as IκBα). While these candidates are of putative biological 
significance, given their influence on cell viability, their potential 
role in Melligen cell survival is yet to be elucidated.
RNA transcript levels of different genes were also determined 
after 24 hours of cytokine treatment of the Melligen cells, with 
Figure 7 β-cell transcription factors and pancreatic hormones expressed 
in liver cell lines. (a) RT-PCR detection of mouse β-cell transcription 
factors (Pdx1, Neurod1, Neurog3, Nkx2-2, Nkx6-1, Pax 4, Pax 6, MAFA, MAFB), 
the pancreatic endocrine hormones: insulin (Ins), somatostatin (Sst), 
glucagon (Gcg) and pancreatic polypeptide (Ppy); GLUT 2 (Slc2a2) and 
liver glucokinase (L-Gck); islet glucokinase (I-Gck), insulin proconvertases 
1 and 2 (Pc1 and Pc2); exocrine marker p48 and Actb in Huh7 cells (lane 
1), Huh7ins cells (lane 2), Melligen cells (lane 3) and human islets (lane 
4). (b) RT-PCR analysis of human insulin and human islet glucokinase in 
transplanted Huh7ins cells (lane 1), transplanted Melligen cells (lane 2) and 
human islets (lane 3); (c) RT-PCR analysis of cytokine receptor expression, 
IFNR1, IFNR2, IL1R1, IL1R2, TNFR1 and TNFR2, in human islets (lane 1), 
Huh7 cells (lane 2), Huh7ins cells (lane 3), and Melligen cells (lane 4). 
RT-PCR, real-time polymerase chain reaction.
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untreated cells used as a control. Exposure of the Melligen cells to 
the same combination of cytokines for 24 hours significantly modi-
fied the expression of 148 genes. The 148 genes identified are pre-
sented in Supplementary Table S3. The large majority of the modi-
fied genes (140 of 148) were upregulated (P < 0.05) upon cytokine 
treatment and mainly represented genes known to be inducible by 
IFN-γ, TNF-α, and IL-1β.
To further validate the results of the microarray analysis, five 
genes were selected for validation of the observed gene expres-
sion changes by qRT-PCR. These were genes not previously found 
to be differentially expressed in the cytokine-treated parental cell 
line Huh7, as determined in the literature. These genes were also 
involved in the highest scoring networks established by ingenuity 
pathway analysis (results not included).
qRT-PCR analysis was performed on five of the genes detected 
by the gene array to be upregulated by more than twofold and 
with a significance level of P < 0.05. The five genes, BIRC3, CASP1, 
IRF1, SOD2, and STAT1, were selected from the cascades identi-
fied above and on the basis of their potential involvement in the 
resistance of these cells to cytokine toxicity. The genes selected 
were also genes that had been shown to play pivotal roles in the 
effects of, and signaling pathways regulated by, IFN-γ, TNF-α, 
and IL-1β singly and in combination in the β-cell death occurring 
in T1D (Program, IPA). IRF1 and BIRC3 were also upregulated at 
both 1 and 24 hours.
The results obtained by qRT-PCR confirmed the upregulation 
of BIRC3, CASP1, IRF1, SOD2, and STAT1 by the 24 hours cytokine 
treatment of Melligen cells. Following normalization with β-actin 
mRNA levels, there was a significant (P < 0.05) upregulation of BIRC3 
by 11.5 ± 2.4-fold (n = 8) and this was the highest recorded fold 
change in gene expression of the five genes selected. It was found 
that CASP1, IRF1, SOD2, and STAT1 were upregulated by 2.0 ± 0.4, 
5.4 ± 1.3, 4.5 ± 0.4, and 2.4 ± 0.3-fold, respectively. To determine if the 
absence of the insulin and glucokinase gene expression in the liver 
cell line regulated the five selected genes to the same level, Huh7 
cells were treated with the TCCM for 24 hours. mRNA was extracted 
and used to quantitate expression of the genes of interest by qRT-
PCR. The results showed that BIRC3, CASP1, IRF1, and SOD2 were 
significantly upregulated (P < 0.05) in the Melligen cells, as com-
pared to the Huh7 cells, but no significant difference was found for 
STAT1 gene expression between the cell lines.
DISCUSSION
If artificial β-cells are to be a viable alternative for pancreatic β-cell 
replacement in T1D, they must be endowed with the physiologi-
cal characteristics of pancreatic β-cells; namely biologically active 
insulin production, insulin storage and glucose-dependent insulin 
secretion, and resistance to the cytotoxic effects of proinflamma-
tory cytokines. The Huh7ins cell line possessed some of these char-
acteristics, but they were responsive to low physiological glucose 
concentrations (2.5 mmol/l). In order to produce a more clinically 
viable cell, we investigated the effect of stable expression of the 
human islet glucokinase transgene, which resulted in the produc-
tion of the Melligen cells.
In pancreatic β-cells the low expression of hexokinase results in 
low glycolytic flux and low ATP/ADP levels at glucose levels <2.5 
mmol/l,26,27 which maintains a low basal rate of insulin secretion 
and prevents hypoglycemia. At glucose levels >2.5 mmol/l, β-cells 
phosphorylate glucose via the high-affinity glucokinase, which cor-
relates with the increase in the ATP/ADP ratio of 5–10 mmol/l,27 and 
allows the β-cell to maintain blood glucose levels as they are very 
sensitive to blood glucose levels near the normal fasting glucose 
range. Figure 1 clearly shows that the expression of human islet 
glucokinase in Huh7ins cells (Melligen cells) resulted in a clear 
shift in the glucose dose–response curve to the right. The Melligen 
cells commenced secretion of insulin to glucose at 4.25 mmol/l, 
rather than 2.5 mmol/l for the Huh7ins cells. This shift in the glu-
cose dose–response curve is undoubtedly related to the notice-
able shift in the glucokinase to hexokinase ratio clearly seen in the 
glucose phosphorylation studies. In the presence of glucose-6- 
phosphate, Melligen cells exhibited a threefold enhancement in 
activity (Figure 5b), over the activity in Huh7ins cells and other liver 
cell lines tested. In Melligen cells, the greater proportion of the total 
glucose phosphorylating capacity (58%) was provided by glucose-
6-phosphate insensitive glucokinases, rather than hexokinase, as 
seen in the Huh7 and Huh7ins cells. Studies have shown that high 
glucose concentrations in isolated islets cause increased glucoki-
nase activity and parallel increases in the capacity of glucose-stimu-
lated insulin release.28 While insulin storage in the Melligen cells was 
not altered, they secreted twice as much insulin to glucose over the 
course of the dose–response curve.
Animals transplanted with Melligen cells maintained normoglyce-
mia from day 19 onwards and exhibited a normal glucose response 
curve, which was not significantly different to that observed for 
nondiabetic animals. By comparison, animals transplanted with 
Huh7ins cells became hypoglycemic from day 21 onwards and the 
glucose tolerance curve peaked at significantly lower levels when 
compared to animals transplanted with Melligen cells or untreated, 
nondiabetic controls, returning to hypoglycemic levels by 120 min-
utes. The development of hypoglycemia and abnormal glucose tol-
erance seen in this study after diabetic animals were engrafted with 
Huh7ins cells, and in our previous study,4 is most likely attributed to 
their secretion of insulin in response to glucose at subnormal fast-
ing levels (2.5 mmol/l). However, it is likely that if the Melligen cells 
were maintained for an extensive period in vivo, they would con-
tinue to proliferate and eventually render the animals susceptible 
to hypoglycemia due to the constitutive insulin secretion from the 
mass of cells. Any potential clinical application of Melligen cells to 
cure T1D would require microencapsulation technology to ensure 
that the cells are contained at the site of administration, due to 
their tumorigenic nature causing continual cell proliferation, and to 
protect them from interaction with the cellular arm of the immune 
system. Given that Melligen cells have been shown to be resistant 
to the cytotoxic effects of the cytokines responsible for mediating 
β-cell death in T1D, it suggests that protecting them from cellular 
contact with autoimmune mediators may be sufficient to ensure 
their continued viability post-transplant, however further stud-
ies are required to assess this. Of critical importance, it was noted 
that the human insulin and human islet glucokinase transgenes, 
expressed under the control of the cytomegalovirus promoter 
in both constructs, were stably expressed for the duration of the 
in vivo experiment using the NOD/scid mouse model. Thus, Melligen 
cells were able to retain their ability to function as artificial β-cells 
akin to pancreatic β-cells largely via the continued expression of 
glucokinase.
Melligen cells maintained a β-cell-like phenotype, as is seen 
in the Huh7ins cells,4,29 by developing secretory granules of simi-
lar appearance and size to those of pancreatic β-cells together 
with a regulated insulin secretory mechanism. This has undoubt-
edly arisen from the expression of insulin against a background 
of endogenous expression of pancreatic cell transcription factors 
and β-cell proteins that are present in the dedifferentiated paren-
tal Huh7 cell line. Numerous studies have shown pancreatic trans-
differentiation of liver cells upon expression of β-cell transcription 
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factors and we have shown spontaneous expression of β-cell tran-
scription factors, pancreatic transdifferentiation, and reversal of dia-
betes in several animal models following the lentiviral delivery of 
furin cleavable insulin.9,11,30 We have previously described the pres-
ence of GLUT2, liver glucokinase, PC1 and PC2, and the pancreatic 
β-cell transcription factors, Pdx1, NeuroD1, Neurogenin 3, Pax4, Pax6, 
Nkx6.1, in Huh7ins cells.4,29 As expected, human islet glucokinase 
was expressed in the Melligen cells, at both the RNA and protein lev-
els, but was not expressed by the parental cell lines. There was little 
difference in the pattern of expression of β-cell transcription factors 
by Melligen cells and Huh7ins cells, except for significant upregula-
tion of expression levels of Pdx1 and GLUT2 and the expression of 
somatostatin and Pax6 in Melligen cells. The increased expression 
of GLUT 2 is likely related to the overexpression of the islet glucoki-
nase and the shift in the balance of the glucokinase to hexokinase 
ratio in the Melligen cell line. Triple immunofluorescent staining 
also showed the presence of the three pancreatic hormones, insu-
lin, glucagon, and somatostatin, in Melligen cells, while only insulin 
protein was detected in Huh7ins cells after transplantation. These 
data suggest that Melligen cells possess a more pancreatic-prone 
phenotype, as compared to Huh7ins cells. The reason for this obser-
vation is unknown, possibly the cells have undergone further trans-
differentiation during the transfection process and we are currently 
investigating possibilities in our laboratory. Extensive pancreatic 
transdifferentiation has been reported on lentiviral transduction of 
liver cells9,11,30 and when liver cells are exposed to toxins31 and high 
levels of glucose.32 By comparison to human insulin (75% of the cells 
in the graft), the levels of human glucagon and somatostatin were 
extremely low (1 and 0.1% respectively) and it is doubtful that they 
had any significant biological effect by comparison to the normal 
production of these hormones from the mouse pancreas.
The proinflammatory cytokines used in this study have estab-
lished roles in the induction of β-cell death and metabolic dys-
function in primary human islet cells, both in vivo and in vitro.33,34 
The results from the MTT viability assay and the insulin storage 
and secretion data over an extended time period indicated that 
the cocktail of proinflammatory cytokines exerted no significant 
effect on the viability, insulin secretion and storage, and the glu-
cose-responsive insulin secretion of the Huh7ins and Melligen cell 
lines. By comparison, the control pancreatic cell line, MIN6, was 
significantly affected, and following 10 days exposure was no 
longer capable of secreting insulin in response to glucose. These 
results corroborate an earlier study of the effect of cytokines on 
another insulin-secreting cell line, HEPG2ins/g.3 The resistance of 
the Huh7ins and Melligen cells to the detrimental effects of pro-
inflammatory cytokines was not likely attributable to decreased 
expression of their cognate receptors as the cytokine receptors 
were shown to be expressed, at least at the RNA level.
Cytokines, such as IFN-γ, TNF-α, and IL-1β, stimulate iNOS expres-
sion and nitric oxide production leading to β-cell damage and 
death. In contrast to MIN6 cells, Huh7, Huh7ins, and Melligen cells 
did not produce increased levels of NO at either 24 or 48 hours. 
Similarly, Chang et al.35 identified downregulated iNOS gene expres-
sion in cytokine-treated rat hepatocytes. Therefore, the time-points 
for microarray analysis in this study were chosen from the previous 
studies,35–37 which indicated that early and relevant changes in the 
gene expression profile of insulin-secreting cells were particularly 
evident at both 1 and 24 hours after cytokine exposure.
Cytokine treatment for 6 and 24 hours, as shown by Cardozo 
et al.38, confirmed the up- and downregulation of several functional 
genes in primary rat pancreatic β-cells, including those involved in 
metabolic function, such as GLUT2 and glucokinase. Similarly, the 
microarray study by Sarkar et al.36, performed on human pancre-
atic islets, showed metabolic perturbations after treating the islets 
with IFN-γ, TNF-α, and IL-1β. The changes induced by the cytokines 
include changes in expression of genes involved in glucose trans-
port and responsiveness, GLUT2, and glucokinase. However, in addi-
tion to the upregulation of proapoptotic genes, as seen in a study 
by Cardozo et al.39, there have also been reports of an upregulation 
of antiapoptotic genes, including BIRC3 and TNFAIP3, in other stud-
ies.36,37 In the present study, metabolic mechanisms involving GLUT2 
and glucokinase molecular expression were not altered in Melligen 
cells at 1 or 24 hours, suggesting that these cells may be protected 
against the defects in glucose metabolism that cytokines otherwise 
cause in primary rat and human β-cells at these specific time points. 
Overall, the microarray analyses revealed that 148 genes were dif-
ferentially expressed and were putatively regulated by the cytokine 
cocktail of IFN-γ, TNF-α, and IL-1β after 24 hours of treatment with 
only 18 genes differentially expressed after 1 hour treatment. Some 
of these genes are of immunological significance, and, accordingly, 
their upregulation may have contributed to the ability of Melligen 
cells to resist the cytotoxic effects of proinflammatory cytokines; 
however, this will require further investigation.
To further elucidate the mechanism underlying the resistance 
of the Melligen cells to the cytokine treatment in the current 
study, the effect of cytokine attack in liver cells both in vivo and 
in vitro at a gene level was determined from the literature. In acute 
liver failure or acute viral hepatitis, hepatocytes are exposed to 
elevated levels of several proinflammatory cytokines. These cyto-
kines, notably TNF-α, can activate both cell survival and apoptotic 
pathways in primary rat hepatocytes.39 In primary rat hepatocytes 
treated with IFN-γ, TNF-α and IL-1β, it has been demonstrated 
that the expression of members of the IAP family are regulated 
by NF-κB. This family includes BIRC3, cIAP1, X chromosome-linked 
IAP (XIAP), Survivin11, and Livin12 (ref. 40). As determined by a 
microarray on HepG2 cells, with TNF-α treatment for 6 hours, 
BIRC3 was induced by the cytokine associated with NF-κB and 
the overexpression of BIRC3 was shown to inhibit apoptosis in 
this liver cell line.41 Together, these studies identify pathways, at 
a gene level, that have been shown to protect liver cells against 
cytokine induced cell death. Supporting the prevalent hepatocyte 
phenotype maintained by the Melligen cells, the results from this 
study showed an increased expression of BIRC3 after both 1 and 
24 hours cytokine treatment, which may have contributed toward 
protection against cytokine-induced cell death.
Under proinflammatory conditions, the insulin-secreting 
Melligen cells function efficiently and resist cytokine-induced 
cell death. Depending on cell type, the effects of NF-κB upregu-
lation have been shown to be both proapoptotic or antiapop-
totic. The dichotomy of NF-κB may be the mechanism by which 
the Melligen cells are protected compared to the β-cells that 
are otherwise susceptible to the proinflammatory cytokines. 
The microarray data showed that indeed there are genes dif-
ferentially expressed after cytokine treatment and that some 
of these genes are also differentially expressed in the Melligen 
predecessor, Huh7. Furthermore, the gene array established that 
glucose metabolism in the Melligen cells was not affected by the 
cytokine treatment at either 1 or 24 hours treatment indicating 
desirable cell function notwithstanding the presence of an auto-
immune attack. Although the Melligen cells have become more 
β-cell like, they respond to cytokine treatment more as liver cells 
and not as β-cells since they have the ability to inhibit apoptotic 
function based on their gene expression profile. Comparing the 
five candidate genes by real-time qRT-PCR, results revealed that 
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the presence of the β-cell autoantigen (insulin) and the presence 
of glucokinase do affect the Melligen cells at a molecular level in 
response to proinflammatory cytokines.
The ability of the Melligen cells to maintain viability in a clinical 
environment will need to be confirmed by further in vivo studies, uti-
lizing an appropriate encapsulation system that will protect the cells 
from destruction by the immune system and protect the recipient 
from the tumorigenic nature of the cell. Strategies such as the future 
engineering of a suicide gene, which would, on activation, destroy 
transplanted cells in a clinical setting, are also a consideration. The 
utilization of Melligen cells or other nonpancreatic artificial β-cells 
as a cure for T1D will have an advantage over current insulin therapy 
regimes, in that the new technology will avoid the autoimmune pro-
cess and mimic the natural physiological secretion of insulin from 
the pancreas, delivering the insulin first to the liver and then to the 
peripheral tissue in response to a glucose load, whereas the insulin 
delivered by injections or pumps reaches the peripheral tissue first 
and not the portal circulation. This should both reduce complica-
tions by reducing glucose excursions and narrowing the range of 
glucose concentrations tissues such as the eyes and kidneys are 
exposed to. This technology would also have the advantage over 
studies that deliver β-cell transcription factors to the liver, avoiding 
the need for the use of viral vectors and issues such as exocrine dif-
ferentiation of liver tissue resulting in hepatitis-like syndromes7 and 
abnormal glucose tolerance seen in a number of studies.42 Thus, 
Melligen cells represent a truly regulated insulin-secreting liver cell 
line that responds to glucose in the physiological range and provides 
important information regarding the minimal molecular machinery 
required to generate an artificial β-cell.
MATeRIAlS AND MeTHODS
Plasmid construction and transfection
Human islet glucokinase cDNA contained in the pBluescript commercial 
vector was a gift from Dr M. Alan Permutt, the University of Washington (St 
Louis). The human islet glucokinase cDNA was isolated from pBluescript 
SK+ by digestion with EcoR1. The 2733 bp fragment containing the human 
islet glucokinase cDNA was inserted into the pIRESpuro3 expression vector 
(Clontech,  Clayton, Australia)  at the EcoR1 site (971–972 bp).
Huh7ins cells were transfected with the pIRESpuro3-glucokinase con-
struct, or the pIRESpuro3 vector alone (Huh7ins-empty vector), using 
Effectene transfection reagent, following the manufacturer’s instructions 
(Qiagen, Doncaster, Australia). The eukaryocidal antibiotic puromycin 
(1.1 μg/ml) was added to the cultures 24 hours after transfection. Culture 
medium plus drugs were changed every 2–3 days and after 14 days of selec-
tion, colonies were isolated and expanded. The cells containing the pIRE-
Spuro3-glucokinase construct will hereafter be referred to as Melligen cells.
Cell culture
Huh7ins cells were cultured as monolayers in Dulbecco’s modified Eagle’s 
medium (Life Technologies, Mulgrave, Australia) supplemented with 
10% (v/v) fetal calf serum  (Life Technologies), and 0.55 mg/ml G418 (Life 
Technologies), in 5% CO2, as previously described.
4 Additionally, 1.1 μg/
ml puromycin (Life Technologies) was added to the Melligen cell culture 
medium. MIN6 cells19 were cultured as monolayers in Dulbecco’s modified 
Eagle’s medium containing 20% (v/v) fetal calf serum in 5% CO2 in air. Donor 
pancreas tissue was collected, with permission (Human Ethics Committee, 
Westmead Hospital, Sydney), and human islets were extracted from the 
whole donor pancreas by a modified Edmonton method, using an aphae-
resis unit and were separated on density gradients.43 Islets were frozen in 
liquid nitrogen until use.
Acute stimulation of insulin secretion
Before stimulation, 5 × 106 cells (Huh7, Huh7ins, Huh7ins-empty vector, and 
Melligen cells) were plated into six-well plates and grown overnight. Tissue 
culture plates were thoroughly washed with basal medium (phosphate-
buffered saline (PBS) containing 1 mmol/l CaCl2 supplemented with 20 
mmol/l 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 2 mg/
ml bovine serum albumin, and 1.25 mmol/l glucose) to remove all traces of 
culture medium and fetal calf serum. To stabilize the basal secretion of insulin, 
monolayers were incubated in the basal medium (pH 7.4) for two consecutive 
periods of 1 hour. Dose–response curves were constructed after monolayers 
were exposed to increasing glucose concentrations (1.25–20 mmol/l) for 1 
hour. Glucose was dissolved in basal medium, and basal medium alone was 
used as a control.
Insulin secretion and storage
Huh7ins-empty vector cells and Melligen cells were washed with PBS, and 
harvested by trypsinization. Insulin was extracted overnight in acid/ethanol, 
as previously described.4 Levels of human insulin were measured using an 
Eliza kit (EZHI-14K, Merck Millipore, Bayswater, Australia) which has no cross-
reactivity with human proinsulin and mouse insulin secreted by MIN6 cells 
was measured with the EZRMI-12K kit (Merck Millipore).
Treatment of cells with cytokines
The recombinant human (h) cytokines, TNFα, IL-1β, and hIFNγ, and murine 
(m) IFNγ (as IFNγ is species-specific) were purchased from Biosource Int. 
(Camarillo, CA) TNFα and IL-1β were dissolved in PBS containing 0.1% (w/v) 
bovine serum albumin to obtain stock solutions of 1.1 × 106 and 5 × 105 U/
ml respectively. IFNγ was dissolved in 10 mmol/l acetic acid containing 0.1% 
bovine serum albumin to obtain a stock solution of 1 × 105 U/ml. The murine 
glucose-responsive MIN6 cell line19 was used as the control pancreatic β-cell 
line to confirm the efficacy of the cytokines. In order to establish the optimal 
cytokine concentration, initial experiments used serial dilutions of single 
cytokine concentrations of mIFN-γ, TNF-α, and IL-1β on MIN6 cells. The effec-
tive doses required to destroy half the MIN6 cell population (ED50) indicated 
on the respective manufacturer’s data sheet for each cytokine constituted 
the most dilute concentration used in generating each cell death curve. 
After establishing the concentrations to be used, the appropriate TCCM 
was made fresh by diluting the stock solutions of TNF-α, IL1β, and IFNγ with 
culture medium to obtain final concentrations of 1,000 U/ml, 374 U/ml, and 
1,000 U/ml, respectively.
Due to the different proliferation rates of the MIN6 cells and the liver cell 
lines, the seeding density for the various cell lines was adjusted accordingly 
to ensure exponential growth of the cells during the timeframe of the exper-
iment. In order to examine cell viability, the MTT assay44 was used in a 96-well 
format. Briefly, Huh7, Huh7ins, and Melligen cells were plated at 1 × 103 cells 
per well (as they proliferated at the same rate, Supplementary Figure S2) and 
MIN6 cells were plated at 2 × 103 cells per well as MIN6 cells proliferated at a 
slower rate than the liver cell lines. The cells were allowed to adhere to the 
bottom of the wells overnight (37 °C/5% CO2). TCCM was added daily and 
cells were assayed for viability on days 1, 2, 3, 6, 8, and 10. To examine insu-
lin secretion and storage in these cell lines, the cells were plated in 12 well 
plates at a seeding density of 5×103 cells per well for Huh7ins and Melligen 
cells and 2×104 cells per well for MIN6 cells. To examine glucose responsive-
ness Huh7ins and Melligen cells were plated in 6 well plates at 1×104 per well 
and MIN6 cells in 12 well plates at 2×104 cells per well. The TCCM was added 
thereafter daily to the treated wells (in triplicate) and fresh media added to 
the control wells (also in triplicate). For each cell line, insulin secretion was 
measured on days 1, 2, 3, 5, 8, and 10. Chronic insulin secretion was deter-
mined by collecting media daily from each plate and pooling with media 
samples collected on preceding days. The volume of media removed from 
each well daily was recorded and the ELIZA was used to measure chronic 
insulin secretion. Cells were harvested to examine insulin storage at day 10. 
Plates of cells treated identically with TCCM were used to determine glucose 
responsiveness at day 10.
Nitric oxide levels in MIN6 cells and liver cell lines treated with TCCM for 24 
and 48 hours were examined by the modified Griess reaction, as previously 
described.45
RT-PCR analyses
For RT-PCR analyses, Huh7, Huh7ins, Huh7ins-empty vector, and Melligen 
cells were snap-frozen in liquid nitrogen. Human islets were used as the 
positive control. Total RNA was extracted using Trizol (Invitrogen, Mulgrave, 
Australia) and samples were treated with DNase I (Invitrogen). Expression 
levels of insulin, other pancreatic hormones (glucagon, somatostatin, pan-
creatic polypeptide), islet and liver glucokinase, and several β-cell tran-
scription factors (Pdx-1, Neurod1, Neurog3, Pax4, Pax6, Nkx2.2, Nkx6.1) were 
determined. The expression levels of insulin and islet glucokinase were also 
examined in the transplanted cells. Expression levels of cytokine receptors 
(IFNR1, IFNR2, IL1R1, IL1R2, TNFR1 TNFR2) and those genes associated with 
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the NF-ĸβ (NF-ĸB inhibitors: IκBα, IκBβ, and IκBε), Fas and iNOS signaling 
pathways were examined in the cell samples ± TCCM treatment for changes 
in gene expression. Human islets were used throughout as the positive con-
trol. Sequences of the primers used are shown in Supplementary Table S1.
Aliquots of cDNA were used as the template for real-time qRT-
PCR using the SYBR GreenER qPCR Supermix (Invitrogen) and a real-
time detection system (Eppendorf Realplex2, Eppendorf, Hamburg, 
Germany). Real-time qRT-PCR reactions contained either primers spe-
cific to the gene of interest or the reference gene, β2-microglobulin 
(Supplementary Table S1). Amplification efficiencies for each primer set 
were determined to be similar. Data were analyzed using the 2−∆∆t method 
where ∆∆CT = (Ct, Target − Ct, Reference)control tissue − (Ct, Target − Ct, Reference)sample tissue. 
The fold change in the target gene expression, normalized to β-actin and rela-
tive to the expression in the control tissue, was calculated for each sample. The 
mean and standard error of fold changes in expression for each gene were 
then determined.
Transcriptomics analysis
Melligen cells were cultured in media alone or treated with TCCM for either 
1 or 24 hours and RNA was isolated using the RNeasy Kit (Qiagen, Doncaster, 
Australia), according to the manufacturer’s instructions. Preparation and 
labeling of cDNA, hybridization, and scanning of the Human Genome 
ST 1.0 arrays were performed according to the manufacturer’s protocol 
(Affymetrix, Mulgrave, Australia). The microarray procedure (labeling reac-
tions, hybridization procedures, reading the signals, and normalization) 
was performed at the Clive and Vera Ramaciotti Centre for Gene Function 
Analysis (University of New South Wales, Australia).
Data obtained from microarray analyses were imported into GeneSpring 
6.1 software (GeneSpring 6.1, Silicon Genetics, Redwood City, CA). The 
fold changes were filtered in the dataset using P value < 0.01 and a signal- 
to-noise ratio >2 in preparation for use in ANOVA statistical analysis. 
Data analysis was performed using Partek Genomics Suite 6.2 software 
(Partek, St. Louis, MO).
Additional filtering (≥ 2-fold change) was applied to identify genes of 
interest, which were further analyzed using Ingenuity Pathway Analysis soft-
ware (Ingenuity Systems, Redwood City, CA). Those genes with known gene 
symbols and their corresponding expression values were uploaded into the 
software. Each gene symbol was mapped to its corresponding gene object 
in the Ingenuity Pathways Knowledge Base. Networks of these genes were 
algorithmically generated based on their connectivity and assigned a score. 
The score takes into account the number of focus genes in the network and 
the size of the network to approximate how relevant this network is to the 
original list of focus genes.
Canonical pathways analysis identified the pathways, from the IPA library 
of pathways, which were most significant in the input data set. The signifi-
cance of the association between the data set and the canonical pathway 
was determined based on two parameters: (i) a ratio of the number of genes 
from the data set that map to the pathway divided by the total number 
of genes that map to the canonical pathway, and (ii) a P value calculated 
using Fisher’s exact test determining the probability that the association 
between the genes in the data set and the canonical pathway was due to 
chance alone. The expression of selected genes (BIRC3, CASP1, IRF1, SOD2, 
and STAT1) were further validated by qRT-PCR. Sequences are listed in 
Supplementary Table S1.
Western blot analysis
Melligen, Huh7ins, Huh7ins-empty vector cells, and human islets were 
centrifuged (200 g for 5 minutes). The cell pellets were suspended in buffer 
I (Tris 10 mmol/l, 20 mmol/l NaH2PO4, 1.0 mmol/l ethylenediaminetetraace-
tic acid, 0.1 mmol/l phenylmethanesulfonyl fluoride, 10 µg/ml pepstatin, 
10 µl/ml leupeptin, pH 7.8), after which the freeze (−70 °C, 10 minutes)—
thaw (37 °C, 10 minutes) cycle was applied three times. The cells were then 
incubated for 20 minutes at 4 °C. Supernatants were collected and pro-
tein concentrations were determined using the Micro BCA protein Assay 
Reagent Kit Life Technologies.
Protein samples (15 μg/30 µl) were electrophoresed on 10% polyacryl-
amide gels for western blot analysis. Glyceraldehyde-3-phosphate dehy-
drogenase (GADPH) was used as a loading control (Life Technologies). 
Separated proteins were transferred to a nitrocellulose membrane (Merck 
Millipore, MA), which was blocked in PBS containing with 5%w/v skim milk 
powder (overnight at 4 °C). After washing (three times, 10 minutes) with PBS 
containing 0.05%v/v Tween 20, nitrocellulose membranes were incubated 
with primary rabbit anti-human glucokinase antibody (1/1,000 dilution) 
(Santa Cruz Biotechnology, Dallas, TX) for 2 hours at room temperature (RT), 
then washed again three times with PBS (0.05% Tween 20). The nitrocellu-
lose membrane was then incubated with a secondary polyclonal (donkey) 
anti-rabbit horseradish peroxidase IgG conjugated antibody (1/800 dilu-
tion) (Sigma-Aldrich, Sydney, Australia) for 1 hour at RT. After washing three 
times with PBS (0.05% Tween20), glucokinase protein expression (52 kDa) 
was visualized using Super Signal Chemiluminescence Substrate (Quantum 
Scientific, Milton, Australia). The membrane was then stripped with 10% 
sodium dodecyl sulfate, 0.5 mol/l Tris HCl (pH 6.8) and β-mercaptoethanol 
and the incubation and detection process was repeated with the loading 
control: anti-GADPH (36kDa) (Merck/Millipore, MA; 1/2,000).
Glucokinase and hexokinase enzyme activity
Glucose phosphorylation was measured in cell homogenates by following 
the conversion of [U-14C] glucose to [U-14C] glucose-6-phosphate as previ-
ously described.46 The individual activities of glucokinase and hexokinase 
were determined by performing duplicate assays, either in the presence or 
absence of 10 mmol/l glucose-6-phosphate, which inhibited low Km hexoki-
nase activity.47
Transplantation of cells
Male NOD/scid mice were obtained from the Australian Research Council 
(ARC) Facility (Perth, Western Australia). Maintenance and experimental 
manipulations were performed in accordance with the National Health & 
Medical Research Council of Australia principles of laboratory care and regu-
lations of the Australian Research Council were approved by the University 
of Technology Sydney. Diabetes was induced by multiple injections of strep-
tozotocin (STZ; 75 mg/kg body weight/day for 5 consecutive days). Animals 
were considered diabetic if blood glucose levels were >20 mmol/l on three 
separate occasions. After treatment, animals were monitored for body 
weight and blood glucose levels.
Animals were in groups of eight for each treatment. The Huh7ins and 
Melligen cells (1 × 107) were initially aspirated into polyethylene tubing (inter-
nal diameter 0.48 mm; external diameter 0.96 mm) attached to a 23-gauge 
needle placed on a Hamilton syringe. The end of the tubing was then inserted 
into the subcutaneous tissues above the right scapula to allow injection of the 
cells into the mice. Blood glucose levels and weight of the mice were moni-
tored every 1–3 days, in the late morning. Insulin was not administered to the 
mice at any time. Grafts were removed from the mice one week after the blood 
glucose levels were normalized (4–5 mmol/l). Blood glucose levels of the mice 
were monitored thereafter with an increase expected if the graft had been 
responsible for reversal of the diabetes. Intraperitoneal glucose tolerance tests 
(2 g glucose/kg after an 18-hour fast) were carried out on the transplanted ani-
mals at 26 days together with diabetic and normal controls.
Microscopic analysis
For immunofluorescence microscopy, frozen sections (6–8 μm) of trans-
planted cells and pancreas were prepared. For triple staining of insulin, glu-
cagon, and somatostatin, the primary antibodies were mouse anti-human 
insulin (1:100; BioGenex, Fremont, CA), goat anti-glucagon and goat anti-
somatostatin (1:200; Santa Cruz, Dallas, TX). The secondary antibodies were 
anti-mouse IgG, and anti-goat IgG (1:200; Vector, Burlingame, CA). The fluo-
resceins were fluorescein avidin D, AMCA avidin D and rhodamine avidin D 
(1:200; Vector). The staining procedure followed the fluorescein M.O.M kit 
(FMK–220, Vector). Between application of the primary antibodies against 
insulin and glucagon and glucagon and somatostatin, the avidin/biotin 
blocking kit (sp-200; Vector) was used, following the manufacturer’s instruc-
tions. All cells in 10 random fields were scored. Data were expressed as the 
number of positive cells per mm2 of tissue.
For electron microscopy, tissue was fixed and processed as previously 
described.9 For insulin immunoelectron microscopy, a postembedding 
immunogold procedure was used. Tissues and cells were embedded in LR 
White (ProSciTech, Thurigawa, Australia) and labeling procedures were per-
formed as previously described.9
Statistical analysis
Data are represented as mean values ± standard error. Comparisons between 
two groups were analyzed using Student’s t-test. Comparisons between 
more than two groups were analyzed using general linear model analysis of 
variance (SPSS 17.0.0, SPSS, 2008, Armonk, NY). Repeated-measures analy-
ses were used where appropriate. P values less than 0.05 were considered to 
be statistically significant.
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